Menopausal Osteoporosis: Screening, Prevention and Treatment

Overview

Journal Singapore Med J

Specialty General Medicine

Date 2021 May 5

PMID 33948669

Citations 50

Authors

Eu-Leong Yong

Susan Logan

Affiliations

Soon will be listed here.

Abstract

Screening for osteoporosis in women can be based on age and weight, using the Osteoporosis Screening Tool for Asians and assessment for other risk factors such as early menopause, Chinese ethnicity and other secondary factors. Based on the resulting risk profile, women can be triaged to dual-energy X-ray absorptiometry (DEXA) scanning for definite diagnosis of osteoporosis. Treatment should be considered in women with previous fragility fractures, DEXA-diagnosed osteoporosis and high risk of fracture. Exercise improves muscle function, can help prevent falls and has moderate effects on improvements in bone mass. Women should ensure adequate calcium intake and vitamin D. Menopausal hormone therapy (MHT) effectively prevents osteoporosis and fractures, and should be encouraged in those aged < 50 years. For women aged < 60 years, MHT or tibolone can be considered, especially if they have vasomotor or genitourinary symptoms. Risedronate or bisphosphonates may then be reserved for those aged over 60 years.

Citing Articles

Neoandrographolide inhibits mature osteoclast differentiation to alleviate bone loss and treat osteoporosis.

Tang K, Deng W, Huang Z, Chen S, Zhu Z, Lin S Front Pharmacol. 2025; 16:1466057.

PMID: 40008134 PMC: 11851123. DOI: 10.3389/fphar.2025.1466057.

MS-275 facilitates osseointegration in osteoporotic rats by mitigating oxidative stress via activation of the miR-200a/Keap1/Nrf2 signaling pathway.

Yan J, Gu Q, Li J, Zhou Z, Jiang W, Guan W Redox Rep. 2025; 30(1):2466142.

PMID: 39973077 PMC: 11843653. DOI: 10.1080/13510002.2025.2466142.

Association of the various physical activity patterns with low bone mineral density in Americans aged 20-60.

Wang Y, Long L, Liu L, Fan P, Zheng X, Li X Arch Osteoporos. 2025; 20(1):23.

PMID: 39945926 DOI: 10.1007/s11657-024-01479-z.

A case-control study based on the National Health and Nutrition Examination Survey to evaluate the effects of human papilloma virus on bone health in women.

Li X, Jiao G, Chen Y BMC Med. 2025; 23(1):75.

PMID: 39920637 PMC: 11806905. DOI: 10.1186/s12916-025-03909-2.

Tea consumption and bone health in postmenopausal women: a systematic review and meta-analysis.

Zhang M, Li S, Wu S, Zhou D, Lu M, Lin C Arch Osteoporos. 2025; 20(1):20.

PMID: 39907867 DOI: 10.1007/s11657-025-01506-7.

References

Beaudoin C, Jean S, Moore L, Gamache P, Bessette L, Ste-Marie L . Number, Location, and Time Since Prior Fracture as Predictors of Future Fracture in the Elderly From the General Population. J Bone Miner Res. 2018; 33(11):1956-1966. DOI: 10.1002/jbmr.3526. View

Brinton L, Felix A . Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol. 2013; 142:83-9. PMC: 3775978. DOI: 10.1016/j.jsbmb.2013.05.001. View

Tella S, Gallagher J . Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2013; 142:155-70. PMC: 4187361. DOI: 10.1016/j.jsbmb.2013.09.008. View

Hadji P, Aapro M, Body J, Gnant M, Brandi M, Reginster J . Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol. 2017; 7:1-12. PMC: 5384888. DOI: 10.1016/j.jbo.2017.03.001. View

Koh L, Sedrine W, Torralba T, Kung A, Fujiwara S, Chan S . A simple tool to identify asian women at increased risk of osteoporosis. Osteoporos Int. 2001; 12(8):699-705. DOI: 10.1007/s001980170070. View

Cheong W, Ji S, Cazenave-Gassiot A, Thu W, Logan S, Cauley J . Predictors of circulating vitamin D levels in healthy mid-life Singaporean women. Arch Osteoporos. 2021; 16(1):26. DOI: 10.1007/s11657-021-00880-2. View

Black D, Rosen C . Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016; 374(3):254-62. DOI: 10.1056/NEJMcp1513724. View

Lydick E, Cook K, Turpin J, Melton M, Stine R, Byrnes C . Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care. 1997; 4(1):37-48. View

Viswanathan M, Reddy S, Berkman N, Cullen K, Middleton J, Nicholson W . Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018; 319(24):2532-2551. DOI: 10.1001/jama.2018.6537. View

10.

Chandran M, Ganesan G, Tan K, Reginster J, Hiligsmann M . Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women. Osteoporos Int. 2020; 32(1):133-144. PMC: 7755873. DOI: 10.1007/s00198-020-05536-4. View

11.

Camacho P, Petak S, Binkley N, Diab D, Eldeiry L, Farooki A . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE . Endocr Pract. 2020; 26(5):564-570. DOI: 10.4158/GL-2020-0524. View

12.

Nelson H, Humphrey L, Nygren P, Teutsch S, Allan J . Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002; 288(7):872-81. DOI: 10.1001/jama.288.7.872. View

13.

Crandall C, Larson J, Cauley J, Schousboe J, LaCroix A, Robbins J . Do Additional Clinical Risk Factors Improve the Performance of Fracture Risk Assessment Tool (FRAX) Among Postmenopausal Women? Findings From the Women's Health Initiative Observational Study and Clinical Trials. JBMR Plus. 2019; 3(12):e10239. PMC: 6894725. DOI: 10.1002/jbm4.10239. View

14.

Manson J, Chlebowski R, Stefanick M, Aragaki A, Rossouw J, Prentice R . Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013; 310(13):1353-68. PMC: 3963523. DOI: 10.1001/jama.2013.278040. View

15.

Pinkerton J, Kaunitz A, Manson J . Concern about US Preventive Services Task Force recommendation on hormone therapy for the primary prevention of chronic conditions in postmenopausal women. Menopause. 2018; 25(5):476. DOI: 10.1097/GME.0000000000001100. View

16.

Adler R, Fuleihan G, Bauer D, Camacho P, Clarke B, Clines G . Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2015; 31(1):16-35. PMC: 4906542. DOI: 10.1002/jbmr.2708. View

17.

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

18.

. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019; 394(10204):1159-1168. PMC: 6891893. DOI: 10.1016/S0140-6736(19)31709-X. View

19.

Sedrine W, Chevallier T, Zegels B, Kvasz A, Micheletti M, Gelas B . Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry. Gynecol Endocrinol. 2002; 16(3):245-50. View

20.

Greendale G, Sowers M, Han W, Huang M, Finkelstein J, Crandall C . Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN). J Bone Miner Res. 2011; 27(1):111-8. PMC: 3378821. DOI: 10.1002/jbmr.534. View